About pulsed magnetic fields see also:



Translation:  Marion Clark 

Source:  AISA Forum [Italian Ataxia Society]


Re:  Therapy with pulsed magnetic fields

From Antonella, December 19, 2008, 1:14 PM 
 
 
 
 
Message from August 25, 2008 (From Maria Litani): 

Therapy with pulsed magnetic fields.

For about a month, I have had a device in my home called the Medithera Home to provide therapy with pulsed magnetic fields—I’m satisfied with it and wanted to let you all know what I’ve been able to experience personally. 

I became aware of this type of therapy thanks to the information shared through BabelFAmily about the Viofor, a product distributed in France, which had been discussed on the French mailing list of AFAF [French Association for Friedreich’s Ataxia].

Sandrine, a patient with FA, informed us of the progress she had made thanks to using that device.

So I invited Daniel Cau, a French distributor, to do a presentation on this product during a meeting organized in Genoa, Italy, on May 10, 2008, by AISA-Liguria [a regional chapter of the Italian Association for Ataxic Syndromes] 

The Viofor was the object of a great deal of interest, and I was planning on getting one.

In the meanwhile, I discovered that there was a product similar to the Viofor, the Medithera Home, which has a sales representative in Italy.  At that time, Medithera Home was being tested at the AISM center in Genoa [one of the Italian Multiple Sclerosis Society’s rehabilitation centers] with a double-blinded study on fatigue in patients with multiple sclerosis.

The Medithera Home consists of a control console that produces a pulsed magnetic field in the applicator, which is a mat to lie down on with a small cushion to position on the part of the body to be treated.  The treatment can be carried out in various modalities, based on the needs. 

My son Stefano (FA, age 30) is using this therapy in the morning and in the evening.

Right away he noticed an improvement in the quality of his sleep.  Now he sleeps calmly, and the contractions he had in his legs, as well as the cramps, have diminished significantly.  Before, I had often needed to stretch his legs during the night.  Sometimes the contractions affected his entire body, including his hands and chest, and they could even block his diaphragm and obstruct his breathing.  Every night he took one and a half 0.25-mg tablets of Lioresal (Baclofen) along with Valium in order to sleep and to relax.

But since a month ago, he no longer takes Valium, and he even sleeps 7-8 hours in a row.  This is just the first benefit, clear and measurable 

There are other positive effects, such as the fluidity of the blood and visual flashes--Stefano no longer sees much at all—however, I still need to verify this effect in order to know if the flashes persist and if they are really a result of the pulsed magnetic fields.

I’m also using the Medithera Home myself, and starting with my first session, the headache I’d had for a full week disappeared.

Periodically I suffer with migraines and vasomotor headaches, but with this treatment, my episodes are less frequent.

In addition, I have dislocated wrists, and I have tendonitis in the left wrist.  Now the tendonitis is gone and I can use my hands to bear weight and to help my son and daughter [who also has FA] to transfer without any problems.

We also have a friend with FA, Eva Aronelius, who suffers from diabetes.  She has used the Medithera Home for over a month.  She too is now able to sleep deeply and without contractions.  In addition, she has noticed a reduction in her glycemic peaks, and she is using less insulin. 

Magnetotherapy will not cure ataxia, but I have reason to believe that it contributes to a much better quality of life for ataxic persons.

Maria Litani, Italy

The legacy of Marie Schlau: literature to help cure Friedreich's Ataxia

If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.

The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.

Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!

https://www.amazon.com/Legacy-Marie-Schlau-collective-Friedreichs-ebook/dp/B01N28AFWZ

 

Research projects currently being financed by BabelFAmily

Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:

1) Gene Therapy for Friedreich's Ataxia research project:

https://www.irbbarcelona.org/en/news/international-patient-advocates-partner-to-fund-spanish-gene-therapy-project-to-treat

The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.

2) Frataxin delivery research project:

https://www.irbbarcelona.org/en/news/new-research-front-to-tackle-friedreichs-ataxia
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.

The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.

 

 

Go to top